← Masimo overview

Masimo vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Masimo Corporation (MASI)

Q3 2026
▲3

Masimo acquired by Danaher; FDA win and Apple patent ruling shape outlook

  • Danaher completes $9.9B acquisition of Masimo Danaher finished buying Masimo for $9.9 billion, and Masimo's stock was delisted from NASDAQ. Shareholders got a premium. Masimo now runs as a standalone unit inside Danaher's diagnostics business, so MASI no longer trades as a separate public stock.

    This is the single biggest event that changes MASI's status and price permanently.

  • FDA clears AI opioid detection on Radius VSM Masimo won FDA clearance for an AI feature that detects opioid-related breathing problems on its wearable monitor. This expands Masimo's product usefulness in hospitals and could drive more sales of its monitoring systems, supporting the value Danaher paid.

    New product approval directly boosts Masimo's growth potential and justifies the acquisition.

  • Apple patent verdict upheld, but trade secret damages denied A judge kept a $634 million patent win for Masimo against Apple, but rejected Masimo's claim for up to $3.1 billion in trade secret damages. Masimo is appealing. The mixed outcome leaves legal uncertainty but preserves a major cash award.

    This legal battle affects Masimo's finances and future royalty income, a key swing factor.

  • Danaher Q2 results show Masimo integration on track Danaher's second-quarter results were solid, with Masimo contributing and helping offset higher debt costs from the acquisition. This suggests Masimo's business is performing as expected inside Danaher, supporting the deal's long-term value.

    Confirms the acquisition is adding value and not dragging on Danaher, which matters for Masimo's future funding and growth.

July 2026
▲3

Masimo acquired by Danaher; FDA win and Apple patent ruling shape outlook

  • Danaher completes $9.9B acquisition of Masimo Danaher finished buying Masimo for $9.9 billion, and Masimo's stock was delisted from NASDAQ. Shareholders got a premium. Masimo now runs as a standalone unit inside Danaher's diagnostics business, so MASI no longer trades as a separate public stock.

    This is the single biggest event that changes MASI's status and price permanently.

  • FDA clears AI opioid detection on Radius VSM Masimo won FDA clearance for an AI feature that detects opioid-related breathing problems on its wearable monitor. This expands Masimo's product usefulness in hospitals and could drive more sales of its monitoring systems, supporting the value Danaher paid.

    New product approval directly boosts Masimo's growth potential and justifies the acquisition.

  • Apple patent verdict upheld, but trade secret damages denied A judge kept a $634 million patent win for Masimo against Apple, but rejected Masimo's claim for up to $3.1 billion in trade secret damages. Masimo is appealing. The mixed outcome leaves legal uncertainty but preserves a major cash award.

    This legal battle affects Masimo's finances and future royalty income, a key swing factor.

  • Danaher Q2 results show Masimo integration on track Danaher's second-quarter results were solid, with Masimo contributing and helping offset higher debt costs from the acquisition. This suggests Masimo's business is performing as expected inside Danaher, supporting the deal's long-term value.

    Confirms the acquisition is adding value and not dragging on Danaher, which matters for Masimo's future funding and growth.

Latest
▲3

Masimo acquired by Danaher; FDA win and Apple patent ruling shape outlook

  • Danaher completes $9.9B acquisition of Masimo Danaher finished buying Masimo for $9.9 billion, and Masimo's stock was delisted from NASDAQ. Shareholders got a premium. Masimo now runs as a standalone unit inside Danaher's diagnostics business, so MASI no longer trades as a separate public stock.

    This is the single biggest event that changes MASI's status and price permanently.

  • FDA clears AI opioid detection on Radius VSM Masimo won FDA clearance for an AI feature that detects opioid-related breathing problems on its wearable monitor. This expands Masimo's product usefulness in hospitals and could drive more sales of its monitoring systems, supporting the value Danaher paid.

    New product approval directly boosts Masimo's growth potential and justifies the acquisition.

  • Apple patent verdict upheld, but trade secret damages denied A judge kept a $634 million patent win for Masimo against Apple, but rejected Masimo's claim for up to $3.1 billion in trade secret damages. Masimo is appealing. The mixed outcome leaves legal uncertainty but preserves a major cash award.

    This legal battle affects Masimo's finances and future royalty income, a key swing factor.

  • Danaher Q2 results show Masimo integration on track Danaher's second-quarter results were solid, with Masimo contributing and helping offset higher debt costs from the acquisition. This suggests Masimo's business is performing as expected inside Danaher, supporting the deal's long-term value.

    Confirms the acquisition is adding value and not dragging on Danaher, which matters for Masimo's future funding and growth.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.